Stockholm, November 17, 2011
Elekta invites equity analysts, investors and media representatives to a Capital Markets Day with focus on emerging markets. Tomas Puusepp, Elekta President and CEO, and other members of Elekta’s management team will give presentations focusing on Elekta’s presence and strategy in emerging markets. Lunch will be served from 12:30 CET and the presentations will start at 13:00 and end at approximately 15:30. The venue is Stockholm Waterfront Congress Centre, Nils Ericsons Plan 4, Stockholm, Sweden.
To attend this Capital Markets Day, please register by e-mail to firstname.lastname@example.org (email@example.com) no later than December 5, 2011.
It will also be possible to follow the Capital Markets Day over the phone and as a live webcast.
Please use the link: http://elekta-livestreampublic.cmm.creo.se/capital-markets-day-2011 (http://elekta-livestreampublic.cmm.creo.se/capital-markets-day-2011)
To take part over the phone, please dial in about 5-10 minutes in advance and use the access code: 703331#.
· Sweden: +46 (0)8 506 269 00
· UK: +44 (0)207 750 9905
· US: +1 866 3059 672
We look forward to your participation on December 12.
VP Corporate Communications
Johan Andersson Melbi
Investor Relations Manager
Elisabeth Natt och Dag
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.